Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most prevalent form of dementia. It affects more than 30 million people worldwide and costs over US$ 1.3 trillion annually. AD is characterized by the brain accumulation of amyloid β peptide in fibrillar structures and the accumulation of hyperphosphorylated tau aggre...
Main Authors: | Débora A. Moreira, Sofia D. Santos, Victoria Leiro, Ana P. Pêgo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/4/1054 |
Similar Items
-
Dendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies
by: Cécile Arbez-Gindre, et al.
Published: (2023-03-01) -
Novel harmine derivatives as potent acetylcholinesterase and amyloid beta aggregation dual inhibitors for management of Alzheimer’s disease
by: Hongtao Du, et al.
Published: (2023-12-01) -
Dendrimer-based banomedicine /
by: Majoros, Istvan J., et al.
Published: (2008) -
H2O2‐responsive multifunctional nanocomposite for the inhibition of amyloid‐β and Tau aggregation in Alzheimer's disease
by: Luying Qiao, et al.
Published: (2023-03-01) -
Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
by: Kaden L. Nystuen, et al.
Published: (2024-01-01)